Have Imazu et al discovered a new clinical biomarker for predicting renal dysfunction in heart failure patients? In this engaging podcast Associate Editor Leon De Windt interviews lead author Masafumi Kitakaze (National Cerebral and Cardiovascular Center, Japan) and expert Thomas Thum (Hannover Medical School, Germany) about the pioneering work by Kitakaze and colleagues, which investigated the correlation between circulating FGF23 in non-ischemic patients with early chronic kidney disease and higher incidences of heart failure hospitalization in these patients. How did inflammation, ischemic conditions, gender, age, and other medications influence circulating FGF23 levels? Listen now.
Miki Imazu, Hiroyuki Takahama, Hiroshi Asanuma, Akira Funada, Yasuo Sugano, Takahiro Ohara, Takuya Hasegawa, Masanori Asakura, Hideaki Kanzaki, Toshihisa Anzai, Masafumi Kitakaze Pathophysiological Impact of Serum Fibroblast Growth Factor 23 in Patients with Non-ischemic Cardiac Disease and Early Chronic Kidney Disease Am J Physiol Heart Circ Physiol, published November 15, 2014. DOI: 10.1152/ajpheart.00331.2014.
More Episodes
2012-06-01
371
2012-05-24
297
2012-05-17
236
2012-05-02
218
2012-04-24
196
2012-04-13
175
2012-04-03
155
2012-03-14
162
2012-02-28
156
2012-02-09
147
2012-02-06
154
2012-02-02
118
2012-01-18
89
2012-01-11
129
2011-12-13
79
2011-11-17
96
2011-11-09
373
Get this podcast on your
phone, FREE
